ST, you're obviously bullish about the drug and fair enough, but...

ST, you're obviously bullish about the drug and fair enough, but you're getting a little carried away and some of your logic is askew. The most obvious issue is your enthusiasm about NNZ-2256 being an analogue of a natural compound. To quote you:

"So why is nnz2256 so special?

Well for a start it is human derived. In fact it already does in healthy humans what we want it to do in brains of our test participants. This doesn’t automatically mean that it will be effective in the clinical trials, but it’s a big advantage."'

Sounds very promising doesn't it. There's a few problems though. For starters, NNZ-2256 is not the naturally produced product. That would be IGF-1, or more specifically, the glypromate part of it that NNZ-2256 is designed to mimic. Now, based on your logic, the best treatment of all would be the truly natural product - IGF-1 or glypromate. Most obvious problem is that as natural products, if NNZ-2256 works, then people might just start using glypromate, or IGF-1 (although IGF-1 has a terrible safety profile)or other analogues instead of paying for NNZ-2256. Not so good for profits.

But they probably won't do that, because Neuren has already conducted trials with Glypromate. Phase 3 trials in fact - - the ones you say would be a sure thing if NNZ-2256 ever got there because its a natural product. Well, the phase 3 trials Neuren conducted with glypromate didn't go so well. They failed, the share price fell 80% and the company discontinued development of the drug. So its a little cheeky to put forward that logic about it being natural in support of NNZ-2256, when exactly the same logic could have been (and was) used to support glypromate in the company's own failed clinical trials that you don't even mention! I understand you're enthusiastic and well done on on riding the SP to its current point, but don't pretend you're laying out the full story when you're skipping whole slabs of history that are directly relevant to the drug and the company and the chances of success of NNZ-2256 in its current and possibly future trials. Oh, and Larry was CEO then too.

Hence ST, when next you do your sums to come up with a fair value for NEU, best to include the minuses as well as the plusses. p.s am still waiting on your claimed evidence of proven efficacy in humans.